Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Shandong Buchang Pharmaceuticals Co's selling, general, & admin. expense for the
three
months ended in Jun. 2026 was ¥743 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was ¥4,556 Mil.
Shandong Buchang Pharmaceuticals Co (SHSE:603858) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Shandong Buchang Pharmaceuticals Co Selling, General, & Admin. Expense Related Terms
Shandong Buchang Pharmaceuticals Co Selling, General, & Admin. Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Buchang Pharmaceuticals Co Selling, General, & Admin. Expense Chart
SHSE:603858 vs ZTS: Selling, General, & Admin. Expense Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Buchang Pharmaceuticals Co's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Buchang Pharmaceuticals Co Selling, General, & Admin. Expense vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shandong Buchang Pharmaceuticals Co's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Shandong Buchang Pharmaceuticals Co's Selling, General, & Admin. Expense falls into.
Shandong Buchang Pharmaceuticals Co Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4,556 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of ¥4,556 Mil mean?
Shandong Buchang Pharmaceuticals Co (SHSE:603858) has a Selling, General, & Admin. Expense of ¥4,556 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Shandong Buchang Pharmaceuticals Co and its competitors.
Is Shandong Buchang Pharmaceuticals Co's Selling, General, & Admin. Expense too high?
Shandong Buchang Pharmaceuticals Co's current Selling, General, & Admin. Expense is ¥4,556 Mil. Overall, Shandong Buchang Pharmaceuticals Co has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shandong Buchang Pharmaceuticals Co's Selling, General, & Admin. Expense compare to ZTS?
Shandong Buchang Pharmaceuticals Co's Selling, General, & Admin. Expense of ¥4,556 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Shandong Buchang Pharmaceuticals Co and its competitors. Shandong Buchang Pharmaceuticals Co's current Selling, General, & Admin. Expense is ¥4,556 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Buchang Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Buchang Pharmaceuticals Co (SHSE:603858) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.35, compared to a current price of ¥14.85 — trading 3.3% below its estimated fair value. The current Selling, General, & Admin. Expense is ¥4,556 Mil. Shandong Buchang Pharmaceuticals Co's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Shandong Buchang Pharmaceuticals Co (SHSE:603858), the current Selling, General, & Admin. Expense is ¥4,556 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Buchang Pharmaceuticals Co (SHSE:603858) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Buchang Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥14.85 is trading 3.3% below its estimated GF Value™ of ¥15.35.
GuruFocus considers Shandong Buchang Pharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:603858:
Selling, General, & Admin. Expense: ¥4,556 Mil
GF Value™: ¥15.35 vs. price of ¥14.85 (3.3% below fair value)
No single metric tells the full story. See the SHSE:603858 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603858 has been successfully added to your 
